No AccessJournal of UrologyOncology: Prostate/Testis/Penis/Urethra1 Jan 2013

Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

View All Author Information


Androgen deprivation therapy is associated with fracture risk in men with prostate cancer. We assessed the effects of toremifene, a selective estrogen receptor modulator, on fracture incidence in men receiving androgen deprivation therapy during a 2-year period.

Materials and Methods:

In this double-blind, placebo controlled phase III study 646 men receiving androgen deprivation therapy for prostate cancer were assigned to toremifene (80 mg by mouth daily) and 638 were assigned to placebo. Subjects were followed for 2 years. The primary study end point was new vertebral fractures. Secondary end points included fragility fractures, bone mineral density and lipid changes.


The 2-year incidence of new vertebral fractures was 4.9% in the placebo group vs 2.5% in the toremifene group, a significant relative risk reduction of 50% (95% CI –1.5 to 75.0, p = 0.05). Toremifene significantly increased bone mineral density at the lumbar spine, hip and femoral neck vs placebo (p <0.0001 for all comparisons). There was a concomitant decrease in markers of bone turnover (p <0.05 for all comparisons). Toremifene also significantly improved lipid profiles. Venous thromboembolic events occurred more frequently with toremifene than placebo with 7 subjects (1.1%) in the placebo group experiencing a venous thromboembolic event vs 17 (2.6%) in the toremifene group. Other adverse events were similar between the groups.


Toremifene significantly decreased the incidence of new vertebral fractures in men receiving androgen deprivation therapy for prostate cancer. It also significantly improved bone mineral density, bone turnover markers and serum lipid profiles.


  • 1 : Cancer statistics, 2008. CA Cancer J Clin2008; 58: 71. Google Scholar
  • 2 : Androgen deprivation therapy for prostate cancer. JAMA2005; 294: 238. Google Scholar
  • 3 : Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer2005; 103: 1615. Google Scholar
  • 4 : Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest2000; 106: 1553. Crossref, MedlineGoogle Scholar
  • 5 : Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med2005; 352: 154. Google Scholar
  • 6 : Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol2005; 23: 7897. Google Scholar
  • 7 : Men and osteoporosis. Accessed July 14, 2010. Google Scholar
  • 8 : The structural basis of bone fragility in men. Bone1999; 25: 143. Google Scholar
  • 9 : Clinical practice: Osteoporosis in men. N Engl J Med2008; 358: 1474. Google Scholar
  • 10 : Assessment of vertebral fractures in osteoporosis research. J Rheumatol1997; 24: 1212. Google Scholar
  • 11 : Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab2002; 87: 599. Crossref, MedlineGoogle Scholar
  • 12 : The protective effects of estrogen on the cardiovascular system. N Engl J Med1999; 340: 1801. Crossref, MedlineGoogle Scholar
  • 13 : Complications of androgen deprivation therapy in prostate cancer. Curr Opin Urol2009; 19: 322. Google Scholar
  • 14 : Toremifene: A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer. Drugs1997; 54: 141. Google Scholar
  • 15 : Toremifene citrate versus placebo for treatment of bone loss and other complications of androgen deprivation therapy in patients with prostate cancer. J Clin Oncol2004; 22. abstract 4597. Google Scholar
  • 16 : SAS/STAT 9.1 User's Guide. Cary, North Carolina: SAS Institute, Inc.2004. Google Scholar
  • 17 : Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst1959; 22: 719. MedlineGoogle Scholar
  • 18 : Statistical Methods in Cancer Research Volume 1- the Analysis of Case-Control Studies: IARC Scientific Publications No. 32. Lyon, France: International Agency for Research on Cancer1980. Google Scholar
  • 19 : The analysis of several 2 x 2 contingency tables. Biometrika1971; 58: 129. Google Scholar
  • 20 : Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial: Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA1999; 282: 637. Google Scholar
  • 21 : Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab2004; 89: 3841. Google Scholar
  • 22 : Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer. J Urol2003; 169: 2008. LinkGoogle Scholar
  • 23 : Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med2007; 146: 416. Google Scholar
  • 24 : Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med2009; 361: 745. Google Scholar
  • 25 : Vertebral fractures predict subsequent fractures. Osteoporos Int1999; 10: 214. Google Scholar
  • 26 : The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population. Osteoporos Int2003; 14: 520. Google Scholar
  • 27 : Diabetes and cardiovascular disease during androgen deprivation for prostate cancer. J Clin Oncol2006; 24: 4448. Google Scholar
  • 28 : Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol2009; 181: 1998. LinkGoogle Scholar